Pavlotsky A, Eidelman A, Barak F, Alon H, Horn Y
Department of Oncology, Assaf Harofeh Medical Center, Zerifin, Israel.
J Surg Oncol. 1989 May;41(1):9-11. doi: 10.1002/jso.2930410106.
We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2-week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicity-related symptoms. Cystoscopic follow-up showed a gradual decline in the presence of tumor to a complete response rate of 87.1% at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.
我们对47例复发性膀胱移行细胞癌患者进行了膀胱内化疗。每次治疗使用20毫克丝裂霉素C，在经尿道切除术（TUR）或诊断性膀胱镜检查后7天进行给药，并每隔2周重复一次，共进行5次，之后再次进行膀胱镜检查。再给予两个类似疗程，总共36周。临床数据显示无毒性相关症状。膀胱镜随访显示肿瘤出现率逐渐下降，在36周时完全缓解率为87.1%。13例先前使用其他药物治疗失败的患者对丝裂霉素C有反应。
